Figure 3. DNAM-1 and IL-7 are required for optimal activation of liver ILC1 after CCl4 injection.

(A) Expression of DNAM-1 on NK cells and ILC1 in the liver (n = 2–5). (B) Expression of Pvr mRNA in the liver of mice before (naïve) and 18 h after CCl4 injection (n = 3–4). (C) Expression of CD69 on ILC1 in the liver of WT and Cd226−/− mice before and 18 h after CCl4 injection. (D) MFI of CD69 on NK cells and ILC1 in the liver of WT and Cd226−/− mice before and 18 h after CCl4 injection (n = 2–5). (E) Expression of CD25 on ILC1 in the liver of WT and Cd226−/− mice before and 18 h after CCl4 injection. (F) MFI of CD25 on NK cells and ILC1 in the liver of WT and Cd226−/− mice before and 18 h after CCl4 injection (n = 2–5). (G) Expression of CD25 on liver ILC1 (left) (n = 2–4) and MFI of CD25 on liver NK cells and liver ILC1 (right) after crosslinking with isotype Ig or anti-DNAM-1 mAb. Data were pooled from 3 experiments (right) (n = 8). (H) Expression of Il7 mRNA in the liver of mice before and 18 h after CCl4 injection (n = 3–4). (I) Expression of CD25 on ILC1 (left) (n = 3) and MFI of CD25 on NK cells and ILC1 (right) in the liver of mice (that had been injected with a neutralizing anti-IL-7Rα mAb or isotype Ig 6 h before and 6 h after CCl4 injection) before and 18 h after CCl4 injection. Data were pooled from 2 experiments (right) (n = 3–6). (J) Plasma concentrations of ALT of mice (that had been injected with a neutralizing anti-IL-7Rα mAb or isotype Ig 6 h before and 6 h after CCl4 injection) before and 18 h after CCl4 injection. Data were pooled from 2 experiments (n = 3–6). (K) Expression of CD25 on liver ILC1 (left) (n = 2) and MFI of CD25 on liver NK cells and liver ILC1 (right) in the absence or presence of IL-7. Data were pooled from 3 experiments (right) (n = 4). Data are representative of 3 (A, G (left), and K (left)), 2 (B, H, and I (left)), and 4 (C-F) independent experiments. *p<0.05, **p<0.01, ***p<0.005. Error bars show s.d.